InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,618.26
(
0.00%
)
US TECH 100
19,247.20
(
2.07%
)
Dow Jones
41,503.10
(
0.00%
)
Brent Oil
73.74
(
1.87%
)
Bitcoin
63,114.77
(
2.34%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 329

Thursday, 08/30/2018 9:19:33 AM

Thursday, August 30, 2018 9:19:33 AM

Post# of 438
RDHL focuses on GI diseases

RDHL reported disappointing Ph3 Crohns Dissease trial results 7/31/18. This trial took the novel approach of treating CD as an
infection rather than a complex inflammation.

The CD treatment space is increasingly competitive. Although safe,
RDHL's approach should include a diagnostic to prove the concept. In any case, it should run another Ph3 trial.

RDHL's H Pylori treatment has a higher probability of success. Trial results for this program will be available Q4/18

Cash runway only extends into H1/19
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up